Hemostemix Inc.
HEM
株式のランク
#32557
Hemostemix Inc., a clinical stage biotechnology company, develops,... Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopathy, chronic limb threatening ischemia, vascular dementia, and brain function. The company also develops NCP-01, which is preclinical trial to evaluate effect on neuropathic pain and motor function recovery. Hemostemix Inc. is headquartered in Calgary, Canada.
株価
$0.04268108
最終同期: 2026-10-21
時価総額
$9.02M
変化（1日）
5.73%
変化（1年）
-42.09%
国
CA
取引 Hemostemix Inc. (HEM)
カテゴリー
Healthcare
Hemostemix Inc.（HEM）の株価履歴
終値の最高値: $0.04 （2026-10-01）
終値の最安値: $0.00 （2005-11-01）
終値の最安値: $0.00 （2005-11-01）
Hemostemix Inc. の株価履歴（2005 ～ 2026）
年間株価パフォーマンス
| 年 | パフォーマンス |
|---|---|
| 2026 (TTM) | -11.95% |
| 2025 | 20.30% |
| 2024 | -2.01% |
| 2023 | -53.19% |
| 2022 | -8.06% |
| 2021 | 925.13% |
| 2020 | 7.84% |
| 2019 | -99.16% |
| 2018 | 984,477.83% |
| 2017 | 242.51% |
| 2016 | -91.14% |
| 2015 | 0.00% |
| 2014 | 0.00% |
| 2013 | 0.00% |
| 2012 | 0.00% |
| 2011 | 0.00% |
| 2010 | -1.41% |
| 2009 | -34.26% |
| 2008 | -72.09% |
| 2007 | 17.99% |
| 2006 | 72.63% |
| 2005 | 0.00% |
類似企業または競合の株価
| 企業 | 株価 | 変化率 1年% | 国 |
|---|---|---|---|
| $536.36 | 25.78% |
US
|
|
| $231.06 | 760.55% |
US
|
|
| $137.83 | -3.78% |
AU
|
|
| $291.76 | 2.51% |
BE
|
|
| $879.87 | 8.07% |
NL
|
